Juan Pablo López-Cervantes, Vivi Schlünssen, Chamara Senaratna, Simone Accordini, Francisco Javier Callejas, Karl A Franklin, Mathias Holm, Nils Oskar Jogi, Andrei Malinovschi, Anna Oudin, Torben Sigsgaard, Elin Helga Thorarinsdottir, Christer Janson, Randi Jacobsen Bertelsen, Cecilie Svanes
{"title":"以人群为基础的 RHINESSA 研究中青春期口腔湿润烟草(鼻烟)的使用及其与哮喘的关系。","authors":"Juan Pablo López-Cervantes, Vivi Schlünssen, Chamara Senaratna, Simone Accordini, Francisco Javier Callejas, Karl A Franklin, Mathias Holm, Nils Oskar Jogi, Andrei Malinovschi, Anna Oudin, Torben Sigsgaard, Elin Helga Thorarinsdottir, Christer Janson, Randi Jacobsen Bertelsen, Cecilie Svanes","doi":"10.1136/bmjresp-2024-002401","DOIUrl":null,"url":null,"abstract":"<p><strong>Objectives: </strong>To investigate the association of early snus use initiation (≤15 years of age) with asthma and asthma symptoms.</p><p><strong>Design: </strong>Cross-sectional analysis of a population-based cohort.</p><p><strong>Setting: </strong>Study centres in Norway, Sweden, Iceland, Denmark and Estonia, from 2016 to 2019.</p><p><strong>Participants: </strong>9002 male and female participants above 15 years of age of the Respiratory Health in Northern Europe, Spain and Australia study.</p><p><strong>Main outcome measures: </strong>Current asthma and asthma symptoms.</p><p><strong>Results: </strong>The median age of study participants was 28 years (range 15-53) and 58% were women. 20% had used snus, 29% men and 14% women. Overall, 26% of males and 14% of females using snus started ≤15 years of age. Early snus use initiation was associated with having three or more asthma symptoms (OR 2.70; 95% CI 1.46 to 5.00) and a higher asthma symptom score (β-coefficient (β) 0.35; 95% CI 0.07 to 0.63) in women. These associations were weak in men (OR 1.23; 95% CI 0.78 to 1.94; β 0.16; 95% CI -0.06 to 0.38, respectively). There was evidence for an association of early snus initiation with current asthma (OR 1.72; 95% CI 0.88 to 3.37 in women; OR 1.31; 95% CI 0.84 to 2.06 in men). A sensitivity analysis among participants without smoking history showed stronger estimates for all three outcomes, in both men and women, statistically significant for three or more asthma symptoms in women (OR 3.28; 95% CI 1.18 to 9.10). Finally, no consistent associations with asthma outcomes were found for starting snus after age 15 years.</p><p><strong>Conclusions: </strong>Snus initiation in puberty was associated with higher likelihood of asthma and asthma symptoms, with the highest estimates in females and those without smoking history. These results raise concerns about the health adversities of early snus initiation and emphasise the need for public health initiatives to protect young people from this tobacco product.</p>","PeriodicalId":9048,"journal":{"name":"BMJ Open Respiratory Research","volume":"11 1","pages":""},"PeriodicalIF":3.6000,"publicationDate":"2024-07-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11268032/pdf/","citationCount":"0","resultStr":"{\"title\":\"Use of oral moist tobacco (snus) in puberty and its association with asthma in the population-based RHINESSA study.\",\"authors\":\"Juan Pablo López-Cervantes, Vivi Schlünssen, Chamara Senaratna, Simone Accordini, Francisco Javier Callejas, Karl A Franklin, Mathias Holm, Nils Oskar Jogi, Andrei Malinovschi, Anna Oudin, Torben Sigsgaard, Elin Helga Thorarinsdottir, Christer Janson, Randi Jacobsen Bertelsen, Cecilie Svanes\",\"doi\":\"10.1136/bmjresp-2024-002401\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Objectives: </strong>To investigate the association of early snus use initiation (≤15 years of age) with asthma and asthma symptoms.</p><p><strong>Design: </strong>Cross-sectional analysis of a population-based cohort.</p><p><strong>Setting: </strong>Study centres in Norway, Sweden, Iceland, Denmark and Estonia, from 2016 to 2019.</p><p><strong>Participants: </strong>9002 male and female participants above 15 years of age of the Respiratory Health in Northern Europe, Spain and Australia study.</p><p><strong>Main outcome measures: </strong>Current asthma and asthma symptoms.</p><p><strong>Results: </strong>The median age of study participants was 28 years (range 15-53) and 58% were women. 20% had used snus, 29% men and 14% women. Overall, 26% of males and 14% of females using snus started ≤15 years of age. Early snus use initiation was associated with having three or more asthma symptoms (OR 2.70; 95% CI 1.46 to 5.00) and a higher asthma symptom score (β-coefficient (β) 0.35; 95% CI 0.07 to 0.63) in women. These associations were weak in men (OR 1.23; 95% CI 0.78 to 1.94; β 0.16; 95% CI -0.06 to 0.38, respectively). There was evidence for an association of early snus initiation with current asthma (OR 1.72; 95% CI 0.88 to 3.37 in women; OR 1.31; 95% CI 0.84 to 2.06 in men). A sensitivity analysis among participants without smoking history showed stronger estimates for all three outcomes, in both men and women, statistically significant for three or more asthma symptoms in women (OR 3.28; 95% CI 1.18 to 9.10). Finally, no consistent associations with asthma outcomes were found for starting snus after age 15 years.</p><p><strong>Conclusions: </strong>Snus initiation in puberty was associated with higher likelihood of asthma and asthma symptoms, with the highest estimates in females and those without smoking history. These results raise concerns about the health adversities of early snus initiation and emphasise the need for public health initiatives to protect young people from this tobacco product.</p>\",\"PeriodicalId\":9048,\"journal\":{\"name\":\"BMJ Open Respiratory Research\",\"volume\":\"11 1\",\"pages\":\"\"},\"PeriodicalIF\":3.6000,\"publicationDate\":\"2024-07-22\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11268032/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"BMJ Open Respiratory Research\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1136/bmjresp-2024-002401\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"RESPIRATORY SYSTEM\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"BMJ Open Respiratory Research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1136/bmjresp-2024-002401","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"RESPIRATORY SYSTEM","Score":null,"Total":0}
引用次数: 0
摘要
目的:研究早期开始使用鼻烟(≤15 岁)与哮喘和哮喘症状的关系:调查早期开始使用鼻烟(≤15 岁)与哮喘和哮喘症状的关系:设计: 基于人群的队列横断面分析:研究中心:挪威、瑞典、冰岛、丹麦和爱沙尼亚,时间为2016年至2019年。参与者:北欧、西班牙和澳大利亚呼吸系统健康研究的9002名15岁以上男性和女性参与者:主要结果指标:目前的哮喘和哮喘症状:研究参与者的年龄中位数为 28 岁(15-53 岁不等),58% 为女性。20%的人使用过鼻烟,其中男性占 29%,女性占 14%。总体而言,26%的男性和 14% 的女性在 15 岁以下开始使用鼻烟。过早开始使用鼻烟与女性出现三次或三次以上哮喘症状(OR 2.70;95% CI 1.46 至 5.00)和较高的哮喘症状评分(β系数 (β)0.35;95% CI 0.07 至 0.63)有关。在男性中,这些关联性较弱(OR 1.23;95% CI 0.78 至 1.94;β 0.16;95% CI -0.06 至 0.38)。有证据表明,早期开始吸食鼻烟与目前患有哮喘有关(女性 OR 1.72;95% CI 0.88 至 3.37;男性 OR 1.31;95% CI 0.84 至 2.06)。对无吸烟史的参与者进行的敏感性分析表明,男性和女性对所有三种结果的估计值都更高,其中女性对三种或三种以上哮喘症状的估计值具有显著的统计学意义(OR 3.28;95% CI 1.18 至 9.10)。最后,15 岁以后开始吸食鼻烟与哮喘结果没有发现一致的关联:结论:青春期开始吸食鼻烟与较高的哮喘和哮喘症状发生率有关,女性和无吸烟史者的估计值最高。这些结果引起了人们对过早开始吸食鼻烟对健康的不利影响的关注,并强调有必要采取公共卫生措施来保护青少年免受这种烟草制品的危害。
Use of oral moist tobacco (snus) in puberty and its association with asthma in the population-based RHINESSA study.
Objectives: To investigate the association of early snus use initiation (≤15 years of age) with asthma and asthma symptoms.
Design: Cross-sectional analysis of a population-based cohort.
Setting: Study centres in Norway, Sweden, Iceland, Denmark and Estonia, from 2016 to 2019.
Participants: 9002 male and female participants above 15 years of age of the Respiratory Health in Northern Europe, Spain and Australia study.
Main outcome measures: Current asthma and asthma symptoms.
Results: The median age of study participants was 28 years (range 15-53) and 58% were women. 20% had used snus, 29% men and 14% women. Overall, 26% of males and 14% of females using snus started ≤15 years of age. Early snus use initiation was associated with having three or more asthma symptoms (OR 2.70; 95% CI 1.46 to 5.00) and a higher asthma symptom score (β-coefficient (β) 0.35; 95% CI 0.07 to 0.63) in women. These associations were weak in men (OR 1.23; 95% CI 0.78 to 1.94; β 0.16; 95% CI -0.06 to 0.38, respectively). There was evidence for an association of early snus initiation with current asthma (OR 1.72; 95% CI 0.88 to 3.37 in women; OR 1.31; 95% CI 0.84 to 2.06 in men). A sensitivity analysis among participants without smoking history showed stronger estimates for all three outcomes, in both men and women, statistically significant for three or more asthma symptoms in women (OR 3.28; 95% CI 1.18 to 9.10). Finally, no consistent associations with asthma outcomes were found for starting snus after age 15 years.
Conclusions: Snus initiation in puberty was associated with higher likelihood of asthma and asthma symptoms, with the highest estimates in females and those without smoking history. These results raise concerns about the health adversities of early snus initiation and emphasise the need for public health initiatives to protect young people from this tobacco product.
期刊介绍:
BMJ Open Respiratory Research is a peer-reviewed, open access journal publishing respiratory and critical care medicine. It is the sister journal to Thorax and co-owned by the British Thoracic Society and BMJ. The journal focuses on robustness of methodology and scientific rigour with less emphasis on novelty or perceived impact. BMJ Open Respiratory Research operates a rapid review process, with continuous publication online, ensuring timely, up-to-date research is available worldwide. The journal publishes review articles and all research study types: Basic science including laboratory based experiments and animal models, Pilot studies or proof of concept, Observational studies, Study protocols, Registries, Clinical trials from phase I to multicentre randomised clinical trials, Systematic reviews and meta-analyses.